Immunotherapy and experimental approaches for metastatic melanoma

被引：30

作者：

Atkins, MB

机构：

[1] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Melanoma & Biol Therapy Programs, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1998年 / 12卷 / 04期

关键词：

D O I：

10.1016/S0889-8588(05)70029-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This article reviews the clinical investigations involving recombinant cytokines (either alone or in combination with adoptive immunotherapy, toxicity reduction agents, or cytotoxic chemotherapy), vaccines, monoclonal antibodies or antibody conjugates, and gene therapy. These various approaches are reviewed for their current and potential roles in curing metastatic melanoma.

引用

页码：877 / +

页数：27

共 154 条

[1]

ABRAHMS PG, 1988, ANTIBODY IMMUNOCON R, V1, P283

[2] Malignant melanoma: Prognostic indicators [J].

Ahmed, I .

MAYO CLINIC PROCEEDINGS, 1997, 72 (04) :356-361

[3] CLASS-II HISTOCOMPATIBILITY ANTIGEN EXPRESSION IN HUMAN MELANOCYTES TRANSFORMED BY HARVEY MURINE SARCOMA-VIRUS (HA-MSV) AND KIRSTEN MSV RETROVIRUSES [J].

ALBINO, AP ;

HOUGHTON, AN ;

EISINGER, M ;

LEE, JS ;

KANTOR, RRS ;

OLIFF, AI ;

OLD, LJ .

JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 164 (05) :1710-1722

[4]

[Anonymous], P AM SOC CLIN ONCOL

[5]

ARGAWALA SS, 1996, CURR OPIN ONCOL, V8, P167

[6] MULTIINSTITUTIONAL PHASE-II TRIAL OF INTENSIVE COMBINATION CHEMOIMMUNOTHERAPY FOR METASTATIC MELANOMA [J].

ATKINS, MB ;

OBOYLE, KR ;

SOSMAN, JA ;

WEISS, GR ;

MARGOLIN, KA ;

ERNEST, ML ;

KAPPLER, K ;

MIER, JW ;

SPARANO, JA ;

FISHER, RI ;

ECKARDT, JR ;

PEREIRA, C ;

ARONSON, FR .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) :1553-1560

[7]

ATKINS MB, 1997, P AN M AM SOC CLIN, V16, P494

[8]

Atkins MB, 1998, MOL DIAGNOSIS PREVEN, P219

[9]

ATKINS MB, 1993, THERAPEUTIC APPL INT, V2, P389

[10]

ATKINS MB, 1997, BIOTHERAPY CONSIDERA, V3, P1

← 1 2 3 4 5 6 7 8 9 10 →